HEK293-PSMA Cells

Unit

3 x 10^6 cells/ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Transformed cell lines

Organism

Human

Donor History

Transformed/immortalized; non-tumorigenic (HEK293 background)

Growth Properties

Monolayer

,

adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS

,

1 mM sodium pyruvate

,

10 mM HEPES

,

1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. Dissociation reagent: Trypsin-EDTA. Seeding density: 2 to 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/HEK293-PSMA-Cells/305992

Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.

HEK293-PSMA cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (FOLH1/GCPII). PSMA is a type II transmembrane glycoprotein with enzymatic folate hydrolase and carboxypeptidase activity that is highly expressed in prostate cancer, particularly in advanced, metastatic, and castration-resistant disease. In addition to prostate malignancies, PSMA expression has also been observed in the neovasculature of various solid tumors. Because of its strong tumor-associated expression and accessible extracellular domain, PSMA has become a major target for diagnostic imaging, radioligand therapy, antibody-based therapeutics, and engineered immune cell approaches.

HEK293-PSMA cells are widely used in oncology research and therapeutic development for characterization of PSMA-targeted monoclonal antibodies, antibody-drug conjugates, radiopharmaceuticals, bispecific T-cell engagers, CAR-T cell therapies, and small-molecule inhibitors. The stable recombinant expression system enables quantitative analysis of ligand binding, receptor occupancy, antigen density, internalization kinetics, and target-dependent cytotoxicity. These cells are particularly valuable for evaluating PSMA-directed imaging probes and radioligand platforms, as PSMA undergoes efficient internalization following ligand engagement. Additional applications include flow cytometry assay development, uptake studies, reporter assays, high-throughput screening, and validation of targeted delivery systems for prostate cancer therapeutics.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.